Ambisome plus miltefosine for Indian patients with kala-azar
Authors:
- Prabhat Kumar SinhaPSPrabhat Kumar Sinha
- Deepak K. VermaDVDeepak K. Verma
- Nawin KumarNKNawin Kumar
- Shahnawaj AlamSAShahnawaj Alam
- Krishna PandeyKPKrishna Pandey
- Poonam KumariPKPoonam Kumari
- Vidyanand RavidasVRVidyanand Ravidas
- Jaya ChakravartyJCJaya Chakravarty
- Neena VermaNVNeena Verma
- Jonathan BermanJBJonathan Berman
- Hashim GhalibHGHashim Ghalib
- 1 February 2011
- journal article
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 105 (2) , 115-117
Abstract
The combination of one intravenous administration of 5mg/kg Ambisome and oral administration of miltefosine, 2.5mg/kg/day for 14 days, was evaluated in 135 Indian patients with kala-azar. The Intent-to-Treat cure rate at 6 months was 124 of the 135 enrolled patients (91.9%: 95% CI = 86-96%), and the per protocol cure rate was 124 of 127 evaluable patients (97.6%: 95% CI = 93-100%). Side effects could be attributed to each drug separately: fevers, rigors and back pain due to Ambisome; gastrointestinal side effects due to miltefosine. This combination is attractive for reasons of efficacy, tolerance, and feasibility of administration, although the gastrointestinal side effects of miltefosine require medical vigilance. Clinical Trials.gov identification number: NCT00371995.Keywords
This publication has 4 references indexed in Scilit:
- Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in IndiaNew England Journal of Medicine, 2010
- New Treatment Approach in Indian Visceral Leishmaniasis: Single‐Dose Liposomal Amphotericin B Followed by Short‐Course Oral MiltefosineClinical Infectious Diseases, 2008
- Injectable Paromomycin for Visceral Leishmaniasis in IndiaNew England Journal of Medicine, 2007
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002